3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
2
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Melanoma
8
Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Basal Cell
2
Urologic Neoplasms
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Urinary Bladder Neoplasms
1
Urinary Bladder Diseases
1
Squamous Cell Carcinoma of Head and Neck
1
Neoplasms by Site
1
Nasopharyngeal Carcinoma
1
Muscle Invasive Bladder Urothelial Carcinoma
1
Melanoma, Cutaneous Malignant
1
Male Urogenital Diseases
1
Locally Advanced Melanoma
1
Female Urogenital Diseases and Pregnancy Complications
1
Female Urogenital Diseases
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Interventions
pembrolizumab
20
Gemcitabine
18
Cisplatin
14
Magnetic Resonance Spectroscopy
13
enfortumab vedotin
12
Specimen Handling
10
Cystectomy
10
Docetaxel
8
Mitomycin
7
Standard of Care
6
Cystoscopy
6
Transurethral Resection of Bladder
5
Radiotherapy
5
Carboplatin
5
durvalumab
4
Practice Guidelines as Topic
4
Nivolumab
4
Radiation
3
Multiparametric Magnetic Resonance Imaging
3
Mitozytrex
3
Fluorouracil
3
tislelizumab
2
dehydroftorafur
2
cemiplimab
2
avelumab
2
alvimopan
2
Therapeutics
2
Surveys and Questionnaires
2
Surgical Procedures, Operative
2
Radiosurgery
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Urinary Bladder Neoplasms
×
relatlimab
×
Clear all
NCT06237920
2025-09-03
TURANDORELA
The Netherlands Cancer Institute
Phase 2
Recruiting
90 enrolled